5.5.2 BERINERT SC (C1-esterase inhibitor; subcutaneous administration) | New Zealand Blood Service
Transfusion medicine

Transfusion medicine handbook

The Transfusion Medicine Handbook is designed to assist hospital staff and other health professionals in modern Transfusion Medicine Practice.

5. Fractionated Products

5.5.2 BERINERT SC (C1-esterase inhibitor; subcutaneous administration)

It is important to distinguish between Berinert and Berinert SC.

Berinert SC does not have full New Zealand registration and so consultation with a NZBS Transfusion Medicine Specialist/Medical Officer is required prior to release of this product. It is supplied by NZBS under Section 29, a provision in the Medicines Act 1981, whereby a medical practitioner can prescribe a medicine that is not registered with Medsafe. Information is available from Germany at https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/berinert-sc-2000-and-3000-au-pi-v500.pdf

Berinert SC is a C1-esterase inhibitor concentrate supplied as 2000 IU or 3000 IU vials (each contains 500 IU/mL when reconstituted). Berinert SC is intended for subcutaneous injection at a rate tolerated by the patient.

Indications for Use

Berinert SC is indicated for prevention of recurrent Hereditary Angioedema (HAE) attacks in patients aged 8 years and older with C1 esterase inhibitor deficiency.

Treatment should be initiated under the supervision of a physician experienced in the management of C1-esterase inhibitor deficiency.

Dosage and Administration

The recommended dose is 60 IU per kg body weight twice weekly (every 3–4 days).

Unsupported Browser!
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.